InflaRx Earnings Call Transcripts
Fiscal Year 2026
-
Izicopan is being advanced as a differentiated oral C5aR inhibitor for AAV and other renal diseases, with a strong safety profile, rapid onset, and potential for once-daily dosing. Clinical trials are designed to demonstrate early efficacy and safety, with regulatory engagement and market expansion strategies underway.
-
Restructuring has shifted focus to izicopan, an oral C5aR inhibitor, with promising phase II-A results in HS and expansion plans for AAV and CSU. Regulatory discussions aim to refine endpoints, and the company is funded into mid-2027 while seeking strategic partnerships.
-
Izicopan, a novel oral C5aR inhibitor, demonstrated rapid, deep, and sustained efficacy in HS and CSU, with a strong safety profile and superior pharmacokinetics compared to avacopan. Market opportunities in HS and ANCA-associated vasculitis are being actively pursued, with FDA discussions ongoing.
-
Izicopan demonstrates strong safety and efficacy signals, with rapid onset and unique benefits in HS. The company is advancing to a phase IIB trial, focusing on HS while exploring CSU and other indications, and has reduced costs to prioritize core programs.
Fiscal Year 2025
-
Positive data for an oral C5aR inhibitor in HS and CSU show rapid, durable efficacy and strong safety, with high-dose groups in HS performing best. The drug differentiates from Avacopan with faster, higher exposure and is advancing to phase 2b trials, supported by a strong cash position.
-
INF904, an oral C5aR1 inhibitor, showed rapid, deep, and durable efficacy in HS and CSU, with a strong safety profile and best-in-class potential. High dose groups achieved significant reductions in lesions, pain, and disease activity, supporting further development in both indications.
-
Upcoming data for a novel oral C5a receptor antagonist in HS and CSU could establish a new standard for efficacy and safety, with rapid onset and broad potential. Strategic partnerships and regulatory support are key to advancing both the antibody and small molecule programs across multiple indications.
-
The presentation highlighted a novel oral C5aR inhibitor, INF-904, with strong preclinical and early clinical data supporting its potential in chronic spontaneous urticaria and hidradenitis suppurativa. INF-904 offers a differentiated profile, large market potential, and a favorable safety outlook.
Fiscal Year 2024
-
GOHIBIC (vilobelimab) showed strong survival benefit in severe COVID-19 and is in a pivotal Phase III trial for pyoderma gangrenosum, with interim results expected in Q2 next year. INF904, a next-generation oral C5aR1 inhibitor, is advancing to Phase IIa studies in HS and CSU, with data anticipated next summer.
-
Upcoming year features key milestones: phase 2a data for INF904 in HS and CSU, and an interim phase 3 readout for Vilobelimab in PG. INF904 shows improved PK/PD and safety over avacopan, while Vilobelimab targets a significant unmet need in PG.
-
The company is advancing C5a/C5aR-targeted therapies in immunodermatology, with late-stage programs in pyoderma gangrenosum and hidradenitis suppurativa, and a new oral candidate entering phase II. Commercial traction for Gohibic in COVID remains challenging, but clinical data and market opportunities in rare skin diseases are promising.